KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Raw Materials (2023 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Raw Materials for 3 consecutive years, with $771000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Raw Materials changed N/A year-over-year to $771000.0, compared with a TTM value of $771000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $1.7 million, down 2.52% over the prior year.
  • Raw Materials was $771000.0 for Q3 2025 at Aurinia Pharmaceuticals, roughly flat from $771000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $1.7 million in Q4 2023 and bottomed at $771000.0 in Q1 2025.
  • Average Raw Materials over 3 years is $1.2 million, with a median of $771000.0 recorded in 2025.
  • Peak annual rise in Raw Materials hit 2.52% in 2024, while the deepest fall reached 2.52% in 2024.
  • Year by year, Raw Materials stood at $1.7 million in 2023, then dropped by 2.52% to $1.7 million in 2024, then crashed by 54.7% to $771000.0 in 2025.
  • Business Quant data shows Raw Materials for AUPH at $771000.0 in Q3 2025, $771000.0 in Q2 2025, and $771000.0 in Q1 2025.